Vælg din region
Vælg den region, der bedst passer til din placering eller dine præferencer.
International
Sverige
Norge
Danmark
Suomi
United Kingdom
Deutschland
France
België
Nederland
Österreich
Schweiz
Italia
España
Vælg dit webstedssprog
Denne indstilling styrer sproget for brugergrænsefladen, inklusive knapper, menuer og al tekst på webstedet. Vælg dit foretrukne sprog for den bedste browsingoplevelse.
Engelsk
English
Svensk
Svenska
Norsk
Norsk
Dansk
Dansk
Finsk
Suomi
Tysk
Deutsch
Fransk
Français
Hollandsk
Nederlands
Italiensk
Italiano
Spansk
Español
Vælg sprog for jobannoncer
Vælg de sprog for jobannoncer, du vil se. Denne indstilling afgør, hvilke jobannoncer der vises for dig.
The two founders still own approximately 75% of the company, the remainder is owned by key persons within the organization. The company is devoted to research and development of bone regenerative technologies and biomaterials. The company is performing early-stage, pre-clinical in vitro and animal studies and all of its inventions are within the field described above. The company’s main assets next to its researchers are its patents and patent applications. Since its inception, the company has successfully developed and licensed out/sold several patent portfolios to major players within the dental implant industry. The Company is focusing all its R & D on its three new technologies, a titanium based ceramic bone graft material (NuBone®), a synthetic peptide family (NuPep™) and a paste for peri-implantitis treatment (NuGel™).